Intermittent treatment regimens in pulmonary tuberculosis

Lung ◽  
1979 ◽  
Vol 156 (1) ◽  
pp. 17-32 ◽  
Author(s):  
M. Zierski
Keyword(s):  
Pulmonary Tuberculosis ◽  
Intermittent Treatment ◽  
Treatment Regimens

scholarly journals The most significant reasons for the failure of treatment of patients with newly diagnosed pulmonary tuberculosis and possible solutions

2020 ◽  
pp. 35-42
Author(s):  
M.M. Kuzhko ◽  
T.V. Tlustova ◽  
D.O. Butov ◽  
M.I. Gumeniuk ◽  
L.M. Protsyk ◽  
...  
Keyword(s):  
Pulmonary Tuberculosis ◽  
Blood Serum ◽  
Maximum Concentration ◽  
Gastrointestinal System ◽  
Newly Diagnosed ◽  
Antituberculosis Drugs ◽  
Treatment Regimens ◽  
Drugs In Blood ◽  
New Treatment ◽  
System Tract

ABSTRACT. The paper summarizes the results of studies regarding the most significant causes of ineffective treatment of patients with newly diagnosed pulmonary tuberculosis. It is proven that the effectiveness of treatment depends from the maximum concentration of antituberculosis drugs in blood serum, tissues and foci of affected lungs, depending on the method of administration of drugs and the presence of concomitant pathology from hepatobiliary and gastrointestinal system tract. Recommendations are given regarding the prevention of ineffective treatment of patients with pulmonary tuberculosis by improving diagnosis and developing new treatment regimens.

scholarly journals Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis

2018 ◽  
Author(s):  
Angeline G Grace ◽  
Abhenil Mittal ◽  
Siddharth Jain ◽  
Jaya P Tripathy ◽  
Srinath Satyanarayana ◽  
...  
Keyword(s):  
Pulmonary Tuberculosis ◽  
Standard Regimen ◽  
Treatment Regimens

INTERMITTENT TREATMENT OF PULMONARY TUBERCULOSIS

The Lancet ◽  
1963 ◽  
Vol 281 (7296) ◽  
pp. 1429-1430 ◽  
Author(s):  
John Mackay-Dick
Keyword(s):  
Pulmonary Tuberculosis ◽  
Intermittent Treatment

scholarly journals Evaluation of Rifapentine in Long-Term Treatment Regimens for Tuberculosis in Mice

1999 ◽  
Vol 43 (10) ◽  
pp. 2356-2360 ◽  
Author(s):  
Anne M. J. A. Lenaerts ◽  
Sharon E. Chase ◽  
Alex J. Chmielewski ◽  
Michael H. Cynamon
Keyword(s):  
Term Treatment ◽  
New Drugs ◽  
Intermittent Treatment ◽  
Bacterial Regrowth ◽  
Treatment Regimens ◽  
Weekly Treatment ◽  
Long Term Treatment ◽  
Apparent Clearance ◽  
Antituberculosis Chemotherapy

ABSTRACT Besides direct bactericidal activity, long-term effectiveness is one of the most important features to consider when developing new drugs for chemotherapy. In this study, we evaluated the ability of rifapentine (RFP), in monotherapy and combination therapy, to completely eradicate a Mycobacterium tuberculosis infection and to prevent relapse posttreatment in a Swiss mouse model. The combination of RFP, isoniazid (INH), and pyrazinamide (PZA) administered daily resulted in an apparent clearance of M. tuberculosis organisms in the lungs and spleens of infected mice after 10 weeks of treatment. However, 3 months after the cessation of therapy, bacterial regrowth occurred in mice treated for a 12-week period, indicating a relapse of infection. In intermittent treatment regimens of RFP in combination with INH and PZA, sterilization was achieved when mice were treated two to five times per week for 9 weeks. Bacterial growth was still observed in the once-weekly treatment group. Our results show that mouse models can predict important parameters for new drugs. We stress the necessity for long-term posttreatment observation in animal models for the routine evaluation of new drugs for antituberculosis chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document